Cara Therapeutics (NASDAQ:CARA) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report released on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of NASDAQ CARA opened at $0.29 on Friday. Cara Therapeutics has a 1 year low of $0.24 and a 1 year high of $1.31. The company’s 50-day moving average is $0.29 and its 200 day moving average is $0.37. The stock has a market capitalization of $15.81 million, a P/E ratio of -0.16 and a beta of 0.68.

Hedge Funds Weigh In On Cara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CARA. XTX Topco Ltd purchased a new position in shares of Cara Therapeutics during the third quarter valued at about $29,000. FMR LLC increased its position in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 32,789 shares during the period. Finally, Disciplined Growth Investors Inc. MN increased its position in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 120,660 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.